StockNews.com Begins Coverage on VolitionRx (NYSE:VNRX)

StockNews.com assumed coverage on shares of VolitionRx (NYSE:VNRX) in a research report sent to investors on Saturday morning. The firm issued a sell rating on the stock.

A number of other equities research analysts also recently commented on VNRX. Benchmark restated a “hold” rating on shares of VolitionRx in a research report on Friday, November 22nd. D. Boral Capital restated a “buy” rating and issued a $5.00 target price on shares of VolitionRx in a research report on Thursday, February 6th.

VolitionRx Stock Down 3.3 %

NYSE:VNRX opened at $0.58 on Friday. VolitionRx has a 52 week low of $0.43 and a 52 week high of $1.17. The company has a market capitalization of $53.75 million, a P/E ratio of -1.61 and a beta of 1.20. The stock’s fifty day moving average is $0.62 and its two-hundred day moving average is $0.65.

Insider Activity

In related news, Director Guy Archibald Innes bought 174,764 shares of the stock in a transaction that occurred on Monday, December 9th. The stock was purchased at an average cost of $0.57 per share, with a total value of $99,615.48. Following the purchase, the director now directly owns 617,085 shares of the company’s stock, valued at $351,738.45. This trade represents a 39.51 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Cameron John Reynolds bought 139,811 shares of the stock in a transaction that occurred on Monday, December 9th. The shares were bought at an average cost of $0.57 per share, with a total value of $79,692.27. Following the completion of the purchase, the chief executive officer now directly owns 2,117,404 shares in the company, valued at $1,206,920.28. This represents a 7.07 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders bought 358,266 shares of company stock valued at $204,212. 12.80% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

An institutional investor recently raised its position in VolitionRx stock. Ground Swell Capital LLC increased its stake in shares of VolitionRx Limited (NYSE:VNRX) by 78.8% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 45,959 shares of the company’s stock after purchasing an additional 20,249 shares during the quarter. Ground Swell Capital LLC’s holdings in VolitionRx were worth $28,000 at the end of the most recent quarter. Institutional investors own 8.09% of the company’s stock.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.